RARE: Ultragenyx Corp PEG Multiple

Corporate company logo of ultragenyx.com (RARE)

Ultragenyx Pharmaceutical (RARE) attracts talent through an ethical mission to treat children, thereby minimizing employee turnover. Business revenues are independent of GDP, determined solely by the approval of new drugs. A strong staff of geneticists is retained through stock options and a unique portfolio. The P/E ratio relative to the company's growth rates demonstrates a market valuation where the current metric equals 0.00, indicating a potential undervaluation of the asset.

Ultragenyx Pharmaceutical (RARE) PEG Multiple: for the period 07/04/2022 - 11/17/2026

Ultragenyx Corp (RARE) - metric breakdowns and financial figures

Summary company analytics:Ultragenyx Pharmaceutical (RARE)
Manufactured products of Ultragenyx Pharma

To assess the fundamental attractiveness of Ultragenyx Pharmaceutical (RARE), an investor must compare the asset's market value with its earnings dynamics. The PEG momentum indicator measures investment efficiency, where values below one signal that the business is undervalued relative to its growth rates, which, combined with the diversified portfolio of gene and protein therapies at Ultragenyx Pharmaceutical (RARE), minimizes patent risks and confirms the company's resilience.

Who Ultragenyx Pharmaceutical competes with

PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|BEAM (Beam Therapeutics Inc) - PEG Multiple|SRPT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Twist Bioscience Corp (TWST)|Price/Earnings to Growth Multiple 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio STOK|BLFS - Price/Earnings to Growth Ratio|Wave Life Sciences (WVE) - Price/Earnings to Growth Multiple|MAZE: PEG Multiple|Sionna Therapeutics, Inc. (SION) - PEG Multiple|Price/Earnings to Growth Ratio Prime Medicine, Inc.|TSHA (Taysha) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple QURE (uniQure Pharma)|Growth-Adjusted Market Cap to Net Income meiragtx.com|Price/Earnings to Growth Ratio REGENXBIO RGNX|SLDB - Price/Earnings to Growth Multiple|Ocugen, Inc. - PEG Multiple|PACB (Pacific Biosciences of California) - Growth-Adjusted P/E Ratio|BNTC: PEG Multiple|DSGN - Growth-Adjusted Market Cap to Net Income|RCKT (Rocket Pharma) - PEG Multiple|Price/Earnings to Growth Ratio FDMT|Price/Earnings to Growth Ratio Lexeo Therapeutics, Inc. (LXEO)|Korro Bio Inc. - Growth-Adjusted P/E Ratio|editasmedicine.com - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income silence-therapeutics.com (SLN)|PRQR: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate codexis.com|SGMO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Nautilus Biotechnology Inc (NAUT)|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Corp (GBIO)|Boundless Bio - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Exicure, Inc. XCUR|Growth-Adjusted Payback Ratio IMNN|PHIO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Mustang Bio Inc MBIO|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Bluebird Bio BLUE|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income